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Abstract
Objective To assess the outcome and associated risks of atrial
defragmentation for the treatment of long-standing persistent
atrial fibrillation (LSP-AF).
Methods Thirty-seven consecutive patients (60.4±7.3 years;
28 male) suffering from LSP-AF who underwent pulmonary
vein isolation (PVI) and linear ablation were compared. All
patients were treated with the Stereotaxis magnetic navigation
system (MNS). Two groups were distinguished: patients with
(n =20) and without (n =17) defragmentation. The primary
endpoint of the study was freedom of AF after 12 months.
Secondary endpoints were AF termination, procedure time,
fluoroscopy time and procedural complications. Complica-
tions were divided into two groups: major (infarction, stroke,
major bleeding and tamponade) and minor (fever, pericarditis
and inguinal haematoma).
Results No difference was seen in freedom of AF between the
defragmentation and the non-defragmentation group (56.2 %
vs. 40.0%,P=0.344). Procedure times in the defragmentation
group were longer; no differences in fluoroscopy times were
observed. Nomajor complications occurred. A higher number
of minor complications occurred in the defragmentation group
(45.0 % vs. 5.9 %, P=0.009). Mean hospital stay was com-
parable (4.7±2.2 vs. 3.4±0.8 days, P=0.06).
Conclusion Our study suggests that complete defragmenta-
tion using MNS is associated with a higher number of minor
complications and longer procedure times and thus compro-
mises efficiency without improving efficacy.
Keywords Atrial fibrillation . Complex fractionated atrial
electrograms . Catheter ablation . Persistent atrial fibrillation
Introduction
Currently, catheter ablation in patients with paroxysmal atrial
fibrillation (AF) in which the pulmonary veins (PVs) are
electrically isolated is a well-accepted treatment and has prov-
en to be successful [1–3]. However, the efficacy of PV isola-
tion (PVI) alone in long-standing persistent AF (LSP-AF) is
poor [4]. Whereas the single procedure drug-free success rate
of PVI in paroxysmal AF ranges between 57 and 80 % [5–8],
in contrast PVI in LSP-AF offers rather low success
rates (21–22 %) [9–11]. Additional ablation lines and other
techniques have been proposed to increase the success rate of
LSP-AF ablation, one of these being atrial defragmentation
[12]. During this procedure electrogram-based ablation is per-
formed. Treatment targeting specific areas in the atrial sub-
strate, showing complex fractionated atrial electrograms
(CFAEs), has also been proposed [13]. Although successful
termination of AF by using this technique alone has been
reported, others have not replicated the encouraging results
of this study [14]. The benefit of PVI and additional linear
ablation in the treatment of LSP-AF has been shown in several
studies [4, 12, 15]. It remains unclear if a combination of PVI
and CFAE ablation significantly increases the success rate of
LSP-AF ablation as opposed to PVI and linear ablation [4, 16].
The aim of this study was to assess whether complete de-
fragmentation is a useful additional technique in order to achieve
a satisfactory clinical outcome in the treatment of LSP-AF.
The questions can be answered after the article has been published in
print. You have to log in to: www.cvoi.nl.
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Methods
This study was a retrospective data analysis. Data from
37 consecutive patients (age 60.4±7.3 years; 28 male)
diagnosed with LSP-AF were compared. Before all proce-
dures a transoesophageal echo was performed to exclude left
atrial (LA) thrombus. Twenty-six patients underwent
radiofrequency catheter ablation for AF at the Erasmus Med-
ical Center in Rotterdam, the Netherlands, and 11 patients
were treated at the Onze Lieve Vrouwe Gasthuis in Amster-
dam, the Netherlands. However, the same team of electro-
physiologists performed all the procedures at two different
locations using identical equipment and procedure strategies.
During the procedure, activated clotting time (ACT) levels
were monitored and were required to be between 275 and
350 s. Patients were divided into two groups: LA ablation
(PVI and linear ablation) with and without defragmentation.
Data on outcome and post-procedural complications were
collected. The primary endpoint of the study was freedom of
AF after 12 months. Secondary endpoints were the following:
acute AF termination, procedure time, fluoroscopy time and
(post) procedural complications. Complications were di-
vided into two categories: major and minor. Major com-
plications were defined as: acute myocardial infarction,
stroke, major bleeding and tamponade. Minor complications
included: fever, pericarditis and inguinal haematoma.
Study population
Only patients with LSP-AF, defined as AF being per-
sistent for 12 months or longer, were included (Table 1)
[17]. Exclusion criteria for this study were: fever or
infection, renal failure (on dialysis or at risk of requiring
dialysis, serum creatinine >200 μmol/l), a malignancy need-
ing therapy or a life expectancy shorter than the duration of the
study. Additional exclusion criteria were intracardiac throm-
bus, severe cerebrovascular disease (neurological deficit of
cerebrovascular cause that persists beyond 24 h), active
gastrointestinal bleeding, bleeding or clotting disorders or
inability to receive heparin and intractable heart failure
(NYHA class IV).
Lastly, patients with an allergy to contrast, patients with
uncontrolled diabetes (fasting blood glucose ≥10.0 mmol/l),
pregnant patients or women of child-bearing potential not
using a highly effective method of contraception and patients
who were unable to attend the outpatients clinic were exclud-
ed from the study. The institutional ethics committee approved
the study protocol and written informed consent was obtained
from all patients.
Follow-up
All patients were followed up for 12 months. They attended
outpatient appointments after 3, 6 and 12 months. An ECG
was obtained at every visit. Before the procedure, a standard
echo and a transoesophageal echo were performed. Data from
the transthoracic echo was used to measure the left ventricular
ejection fraction. Three months before and 12months after the
procedure, patients were fitted with a 24-hour ambulatory
ECG device. The first month before and the third month after
the procedure, patients received a transtelephonic cardiac
event monitor, which they wore for 1 week. Every day pa-
tients submitted their ECG and were instructed to send extra
recordings if they experienced any symptoms. After the first
3 months an assessment was made regarding the use for
antiarrhythmic drugs (AADs). At 6 and 12 months after the
procedure the need for anticoagulants was reassessed
(Table 2).
Treatment arms
PVI with defragmentation All patients were treated with the
Niobe Stereotaxis, Magnetic Navigation System (MNS)
(Stereotaxis Inc., St. Louis MO, USA). The use of this system
has been extensively described in previous reports [18, 19].
Every patient was treated under general anaesthesia because
Table 1 Patient demographics
and procedural parameters Defragmentation No defragmentation P value
Number of patients (n) 20 17
Age (years) 59.2±7.7 61.8±6.8 p =0.28
Male sex (n), (%) 13 (65.0 %) 15 (88.2 %) p =0.10
Years of AF (y) 5.7±6.1 5.6±4.4 p =0.95
Repeat procedures (n), (%) 6 (30.0 %) 2 (11.8 %) p =0.17
Class III antiarrhythmics (n), (%) 13 (65.0 %) 15 (88.2 %) p =0.10
Mean LA diameter (mm) 47.4±5.5 45.1±4.9 p =0.21
Left ventricular ejection fraction (%) 47.8±13.9 52.3±13.1 p =0.66
Mean procedure time (min) 332.5±78.3 261.1±96.6 p =0.02
Mean fluoroscopy time (sec) 58.3±25.8 49.6±20.8 p =0.33
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of the long procedure times and rather extensive and poten-
tially painful ablation. Invasive arterial blood pressure moni-
toring was mandatory throughout the procedure. Pre-ablation
3D images (CT or MRI) were not routinely used as it was not
considered essential for the procedures.
Both groins were prepared for puncture. Intracardiac echo-
cardiography guided transseptal puncture was performed.
Two 8.5 F SL1 (or SL0) sheaths were introduced into the left
atrium. A decapolar catheter was placed into the coronary
sinus. A Lasso catheter (Biosense Webster Inc., Diamond
Bar, CA, USA) was inserted into the left atrium via one
transseptal sheath. Using the second transseptal sheath a mag-
netic irrigated-tip mapping and ablation catheter (RMT
Navistar, Biosense Webster Inc., Diamond Bar, CA, USA)
was inserted in the left atrium.
The left atrium was extensively mapped (density: min 350
equally distributed points) using the MNS system. All PVs
were mapped as separate chambers. Special attention was paid
to the accurate definition of the PV ostia. The ablation se-
quence adhered to the following: First all PVs were isolated.
Then electrogram-based ablation (i.e. defragmentation) in the
left atrium and the coronary sinus was performed at all sites
that displayed any of the following electrogram features:
CFAEs, sites with a significant electrogram offset between
distal and proximal recording bipoles of the mapping catheter
suggesting a local re-entrant wavefront and regions with a
cycle length (CL) shorter than the mean LA appendage CL.
Specific CFAE maps using dedicated software were not
performed.
Endpoint of ablation was in the transformation of fraction-
ated electrograms into discrete electrograms and slowing of
the mean atrial CL compared with LA appendage CL or the
elimination of the electrograms in each region. If AF still
persisted, linear ablation was performed: First a roof line, then
a mitral line and lastly a posteroinferior line. The right atrium
and superior vena cava were targeted for ablation if suspected
to be a source perpetuating AF (lesser prolongation of CL in
the right atrium, resulting in left-right fibrillatory CL gradient)
and only after all LA ablation steps. Endpoint was the elimi-
nation or significant reduction (>75 %) of the local electro-
grams along the ablation lines. After restoration of sinus
rhythm, bidirectional block was assessed at every line using
differential pacing methods. Arrhythmia induction was not
part of this protocol. In case of conversion to a regular atrial
tachycardia, this was targeted for ablation in the same session.
Power settings were conservatively and individually ad-
justed (note: these settings are valid only for ablation using the
MNS). In all regions 25W, 48°, and 30 s with an irrigation rate
of 17 ml was used as initial setup. The bipolar and unipolar
local electrograms were carefully and continuously monitored
during and after every ablation application. If the local elec-
trical activity persisted, the following adjustments were made:
posterior wall: max 35 W, anterior wall: max 40 W, carina, or
other ridge-like structures: max 45 W. At difficult regions
ablation time was extended to 45 s. Thirty minutes after the
last application all PVs were revisited to confirm electrical
isolation.
PVI without defragmentation The same sequence as afore-
mentioned was used, with the exception that after PVI and
additional line ablation defragmentation was not performed.
Statistical analysis
The Kolmogorov-Smirnov test was used to assess the normal-
ity of distribution. Descriptive statistics was presented as
mean ± SD for continuous variables if normally distributed.
Continuous data were compared with the Student’s t test or
Mann-Whitney U test, where appropriate. Categorical data
were presented as percentages and compared with the Fisher’s
exact test. Statistical analysis was performed with PASW
version 18 (IBM Corp., Somers, NY). Statistical significance
was defined as P <0.05 (two-tailed).
Results
Patient population
A total of 37 patients were included. The defragmentation
group had 20 patients and 17 patients were included in the
non-defragmentation group. No differences in age, gender,
years of AF, number of repeat procedure and use of class III
antiarrhythmics were noted (Tables 1 and 3). For the repeat
procedures, a mean number of 1.75±1.75 [range 0–4] PVs
needed to be reisolated. The mean LA diameter of the whole
population was 46.4±5.3 mm. No difference in mean
LA diameter was seen between the two groups (P=0.214,
Table 1). Furthermore, there was no difference in left ventric-
ular ejection fraction between the treatment arms (Table 1).
The mean number of electrical cardioversions in the whole
Table 2 Patient follow-up timeline
Before/after
PVI
Time Activity (ECG on every visit)
Before 3 months 24-hour Holter registration
1 month Transtelephonic cardiac event monitor
1 day Standard echo, transoesophageal echo,
standard blood work
After 3 months Clinical visit, event recorder, AAD check up
6 months Clinical visit, assessment anticoagulants
12 months Assessment anticoagulants, 24-hour Holter
registration
AAD antiarrhythmic drugs
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population was 3.6±3.0. No differences were seen be-
tween the defragmentation and the non-defragmentation
group (3.2±2.1 vs. 4.0±3.7; p =0.404, respectively).
Ablation data
Procedure times in the defragmentation group were longer and
the use of fluoroscopy was comparable between both groups
(Table 1). Themean number of applications for the total group
was 134.2±69.6. A significant difference in the mean number
of applications was seen between the defragmentation group
and the non-defragmentation group (161.9±74.1 vs. 96.5±
41.4, P=0.014). Mean radiofrequency application time from
the whole group was 3438±1664 s. No difference in mean
application time was reported between the defragmentation
group and the non-defragmentation group (3947±1782 vs.
2837±1350 s, P=0.105). Furthermore, no differences were
observed between the two groups in acute AF termination
(70.0 % vs. 76.5 %: P=0.474).
Complications
No major complications occurred in any of the patients. A
significantly higher occurrence of minor complications
was seen in the defragmentation group (45.0 % vs.
5.9 %, P=0.009) (Fig. 1). No difference in type of minor
complications was seen. Patients who experienced complica-
tions received a significantly higher number of radiofrequency
(RF) applications (173.7±69.9 vs. 109.6±58.8, P=0.019). Of
all patients, 8.1 % (n =3) had inguinal haematoma,
8.1 % (n =3) had mild pericardial effusion, 5.4 % (n =2) had
fever and 2.7 % (n =1) had pericardial effusion and fever. In
the defragmentation group, 10.0 % (n =2) had inguinal
haematoma, 15.0 % (n =3) had mild pericardial effusion,
10.0 % (n =2) had fever and 5.0 % (n =1) had mild pericardial
effusion and fever. In the non-defragmentation group 1
(5.9 %) patient had inguinal haematoma. There was no
difference in mean hospital stay between the defragmen-
tation group and the non-defragmentation group (4.7±2.2 vs.
3.4±0.8, P=0.06) (Fig. 2).
Follow-up
For all three moments in time during follow-up (3, 6 and
12 months) no difference was observed in freedom of AF
between the two groups (Fig. 3). After 3 months, 40.0 % of
the patients in the defragmentation group were still in sinus
rhythm, whereas in the non-defragmentation group this was
47.1 % (P=0.611). At 6 months, the number of patients in
sinus rhythm was 50.0 % vs. 35.3 % (P=0.653). After com-
pletion of 12 months of follow-up 56.2 % of the patients from
the defragmentation group were in sinus rhythm and 40.0 % of
the patients in the non-defragmentation group (P=0.344).
During follow-up the use of AADs was comparable for the
two groups (70.0 % vs. 76.5 %, P=0.474) (Table 3). In 13.5 %
Table 3 Use of antiarrhythmics before and after procedure
Defragmentation No Defragmentation All
Before
Amiodarone (n), % 10 (50 %) 13 (76.5 %) 23 (62.2 %)
Sotalol (n), % 5 (25.0 %) 6 (35.3 %) 11 (29.7 %)
After
Amiodarone (n), % 12 (63.2 %) 12 (70.6 %) 24 (66.7 %)
Sotalol (n), % 4 (21.1 %) 3 (17.6 %) 7 (19.4 %)
Fig. 1 Percentage of minor complications for both the defragmentation
and non-defragmentation group
Fig. 2 Average hospital stay presented with standard deviation for patients
in the defragmentation and non-defragmentation group
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(n =5) of the patients a repeat procedure was performed during
follow. During electrophysiology (EP) study one patient had
reconduction in both the left inferior and right superior PV,
another in the right superior PV, another in the left superior PV,
one patient had reconduction of all PVs and in one patient all
PVs were isolated and additional defragmentation needed to be
performed only. During follow-up, 24.3 % of the total popu-
lation experienced atrial tachycardia. This was not statistically
different when compared among the defragmentation and non-
defragmentation group (11.8 % vs. 35.0 %, P=0.103).
Discussion
This is the first study to evaluate the use of complete defrag-
mentation using magnetic navigation in addition to conven-
tional PVI and linear ablation. The major finding is that
defragmentation for the ablation of LSP-AF after PVI and
linear ablation is associated with a higher number of minor
complications and more time-consuming procedures. After
12 months of follow-up no additional effect was observed
for defragmentation therapy regarding freedom of AF. There-
fore, the use of additional defragmentation for LSP-AF com-
promises procedural efficiency without improving efficacy.
Freedom of atrial fibrillation
Achieving satisfactory success rates for ablation of LSP-AF is
very challenging. As demonstrated by Brooks et al. [4], a great
variety of techniques remain available for the ablation of LSP-
AF, including: PVI, pulmonary vein antrum isolation (PVAI)
and different kinds of combinations of these treatments
with ablation lines and defragmentation or CFAE abla-
tion. Several other studies have evaluated the effect of the
implementation of CFAE ablation for LSP-AF [14, 20, 21].
The single-procedure, drug-free success rates from CFAE
ablation alone range from 24 % to 33 % at approximately
1 year. However, no previous study has been performed on the
use of subsequential PVI, linear ablation and defragmentation
for LSP-AF and therefore makes it difficult to compare our
results with previous findings.
Our study suggests that 56.2 % of the patients who had
defragmentation are in sinus rhythm after 12 months of
follow-up. However, most patients in the defragmentation
and non-defragmentation group were on antiarrhythmic drugs
during this period. Nevertheless, these patients suffered from
severe drug-refractory AF prior to the ablation procedure. This
may also explain the incremental increase in percentage of
patients who were in sinus rhythm at 3, 6 and 12 months,
respectively, after defragmentation therapy. In patients who
underwent PVI and linear ablation without additional defrag-
mentation, 40 % were free from AF. Since the difference
between these groups did not meet statistical significance, it
can be concluded that defragmentation therapy in addition to
PVI and linear ablation does not improve outcome of LSP-AF.
Reconduction
One of the largest limitations of ablation for LSP-AF is the
lack of durability of the venous electrical isolation [22]. Prior
studies demonstrated that the majority of patients had recov-
ered venous conduction, which was established during the
repeat procedure [14, 23, 24]. This finding can be supported
by our findings that a significant number of patients who
experienced recurrence had PV reconduction during EP study.
Willems et al. found PV reconduction in approximately 75 %
of patients after the first procedure [25]. For some patients
with LSP-AF the PVs are an important trigger and durable
lesions may improve outcome for these patients. Therefore,
we cannot conclude that defragmentation therapy had no
Fig. 3 The number of patients in
sinus rhythm during follow-up.
Data from three moments in time
are presented (3, 6 and
12 months)
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beneficial effect for patients with LSP-AF at all, since we are
not yet able to perform ablations where durability of the PVI
and linear ablations can be ensured over time. In this study a
limited number of repeat procedures were performed and
therefore we cannot draw conclusions about the specific cause
of low success rates. Possibilities are reconduction after ve-
nous isolation, linear ablation, and insufficient defragmenta-
tion therapy. However, the single procedure success rate after
12 months is not improved by performing defragmentation in
LSP-AF patients.
Amount of defragmentation
Until today, the ideal amount of defragmentation for the
treatment of LSP-AF remains unknown and is highly operator
dependent. Our study demonstrates that additional defragmen-
tation after linear ablation and PVI has no favourable effect on
the outcome. A possible explanation for the ineffectiveness of
defragmentation could be the amount of additional application
time. Our results demonstrate that patients who underwent
defragmentation received a significantly higher number of
RF applications (on average 65 additional lesions). However,
as the mean application time tends to be higher in the defrag-
mentation group with approximately 1000 s of RF ablation, no
statistically significant difference was found regarding total
RF application time. The question rises as to whether more
additional defragmentation would lead to an improved out-
come. In other studies evaluating the effect of defragmentation
in LSP-AF patients the average amount of additional RF
application time was 15–33 min with a total application time
of 54–64 min [14, 26]. Our study achieved comparable results
regarding ablation data with 18.5 min additional defragmen-
tation and a total ablation time of 66 min.
Complications
Although we did not see a higher rate of major complications
associated with defragmentation, as was the case in the study
by Elayi and co-workers [27], we observed a higher number of
minor complications. Pericarditis due to extensive ablation
remains a common complication [28, 29]. Our results demon-
strated that patients who experienced any complications re-
ceived significantly more RF applications (almost 70 more
applications). This increased number of RF applications
(>200) is in some patients responsible for the occurrence of
reactive pericarditis leading to mild pericardial effusion and
fever. Most of the patients, however, recover spontaneously
and are treated conservatively [29]. Considering these com-
plications and the fact that mean hospital stay and more
importantly freedom of AF did not differ significantly accord-
ing to our data could suggest that a certain restraint regarding
the use of defragmentation may be indicated.
Clinical impact
From the findings of this study, the question arises whether
additional defragmentation may not be beneficial for all LSP-
AF patients and should not be performed routinely, but for
selected patients who did not benefit from PVI and linear
ablation. In these individual patients the risk of persisting
AF should be balanced against the risk associated with the
procedure. However, as previously stated by Tilz et al. [30],
our study suggests that the additional risk of complication is
not justifiable for an initial treatment with defragmentation.
When looking at the longer procedure times associated
with defragmentation in our study (with a mean difference
of almost 2 hours), one can conclude that ablation procedures
could be muchmore efficient without this additional treatment
and therefore less burdensome. This supports the findings
concluded by Tilz et al. [30] This might also influence the
cost-efficacy of LSP-AF ablation procedures.
Limitations
In this study a limited number of patients were included and
analysed. However, despite this limited number of patients the
absence of significant differences between the characteristics
suggests homogeneity between the two groups and contrib-
utes to the validity of the conclusions drawn from these
results. Furthermore, patient characteristics from our study
population were in line with those from other studies [4, 14,
27]. To really elucidate the effect of additional defragmenta-
tion in addition to conventional PVI and linear ablation
randomised trials with a higher number of patients are
necessary.
An important issue regarding follow-up which was raised
by Tilz et al. [30] remains whether observed AF recurrence
rates merely depend on the length of follow-up. Like most
studies about LSP-AF ablation, our follow-up lasted for
1 year and therefore does not offer further insight into
this matter [14, 27]. However, longer follow-up would pro-
vide more detailed information on the treatment effect and the
outcomes in the long term. In this study, patients were being
treated with an antiarrhythmic drug during follow-up. Al-
though the use of these drugs was comparable between the
two groups, it might have influenced the outcomes during
follow-up.
Conclusion
The lack of difference in freedom of AF and mean hospital
stay between the two groups and the higher occurrence of
minor complications in the defragmentation group suggests
there is no strong ground to deliver complete defragmentation
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therapy in addition to PVI and linear ablation for patients
suffering from LSP-AF.
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